BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

It can occur for so many reasons, from natural aging to hormonal causes to illness. No matter the culprit, Hims can help. The brand offers doctor-trusted solutions that are proven to deliver ...

It's also gearing up to sell biosimilars of Novo Nordisk diabetes treatment liraglutide. Investors plowed into Hims & Hers stock that day, but Wednesday was a different story. Pouring cold water ...

Meanwhile, the real news — the launch of Hims & Hers’ generic liraglutide at $299 a month — got buried under the buzz. Turns out, this wasn’t a power play; it was a pricing ploy meant to highlight ...

Hims is a telehealth platform for men that offers virtual care for various health concerns. The platform addresses issues such as hair loss, sexual health, weight management, skincare and mental ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...